Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS®


Treatment was not associated with chronic injury, with the average chronicity... | May 9, 2023

Related Keywords

Rockville ,Maryland ,United States ,United Kingdom ,Great Britain ,Greg Keenan ,European Union ,Aurinia Pharmaceuticals Inc ,Aurinia Pharmaceuticals ,Aurinia Pharma Us Inc ,Nasdaq ,Clinical Rheumatology East Conference May ,Chief Medical Officer ,Investor Relations ,Red Cell Aplasia ,Drug Interactions ,Moderate Hepatic Impairment ,Prescribing Information ,Boxed Warning ,Medication Guide ,Aurinia Pharmaceuticals Inc Stock Exchange ,News ,Information ,Press Release ,First ,Study ,O ,Ssess ,Histologic ,Changes ,N ,The ,Kidneys ,F ,Patients ,Ith ,Lupus ,Nephritis ,Reated ,Gas ,Lot ,Ssociated ,Hronic ,Verage Auph Ca05156v1022 ,